Literature DB >> 29185819

Reversal of Glanzmann thrombasthenia platelet phenotype after imatinib treatment in a pediatric chronic myeloid leukemia patient.

Richa Chauhan1, Sudha Sazawal1, Kanwaljeet Singh1, R Ragesh R Nair1, Sunita Chhikara1, Roopam Deka1, Rekha Chaubey1, Karthika Kundil Veetil1, Prasad Dange1, Manoranjan Mahapatra1, Renu Saxena1.   

Abstract

Chronic Myelogenous Leukemia (CML) is a myeloproliferative neoplasm characterized by proliferation of Philadelphia positive clonal pluripotent hematopoietic cells. Bleeding is a rare presentation of CML that can occur due to platelet dysfunction. Both pre-treatment and post-treatment platelet function abnormalities in CML have been described in the literature. We describe a rare case of childhood CML who presented with mucocutateous bleeding manifestations. On laboratory workup, a Glanzmann Thrombasthenia (GT) like platelet phenotype was demonstrated along with confirmation of diagnosis of CML in chronic phase. The acquired nature of platelet function defect was confirmed by demonstrating recovery of platelet antigens glycoprotein IIb/IIIa after achieving complete hematological response with Imatinib. Due to presenting complaint of bleeding diathesis and absence of hepatosplenomegaly, the case was undiagnosed for CML until the patient reported to us. Careful evaluation of complete blood counts, peripheral blood picture and detailed laboratory workup was the window to proper diagnosis and treatment in this case.

Entities:  

Keywords:  Acquired Glanzmann Thrombasthenia (GT); pediatric chronic myeloid leukemia (CML); platelet function defect

Mesh:

Substances:

Year:  2017        PMID: 29185819     DOI: 10.1080/09537104.2017.1384539

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  1 in total

1.  An Unusual Cause of Bleeding in a Patient with Chronic Myeloid Leukemia Chronic Phase.

Authors:  S Kartthik; Prakas K Mandal; Saleh Mohammed Abdullah
Journal:  Case Rep Hematol       Date:  2019-09-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.